Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Calorie Restriction and Brain Function in Mild Cognitive Impairment (5-2CR)

28 marzo 2022 aggiornato da: Auriel A. Willette, Iowa State University

Intermittent Calorie Restriction and Brain Function in MCI

Problems with blood sugar metabolism (i.e., metabolic dysfunction) progressively develop through old age, which is primarily due to obesity and lack of physical activity. Metabolic dysfunction increases the risk for Alzheimer's disease (AD) and negatively impacts memory and related brain function. There is intense interest in developing interventions, particularly non-drug therapies, to combat AD. Recent clinical trials have found that intranasal insulin, which facilitates glucose metabolism in the brain, is able to maintain memory in participants with Mild Cognitive Impairment (MCI), the precursor to AD. While intranasal insulin is a useful, proof-of-concept intervention, it does not affect visceral fat mass and therefore metabolic dysfunction will persist in a given person.

The investigators wish to engage participants with MCI in intermittent calorie restriction (CR), to reduce metabolic dysfunction and improve glucose metabolism. Intermittent calorie restriction in this case refers to eating whatever one wants for 5 days, followed by 2 consecutive days of consuming 530 calories via one protein shake with sufficient nutrients to sustain the person. This results in reliable weight loss, which itself improves glucose metabolism in the body and has a wealth of other benefits. (It should be mentioned here that weight maintenance has been shown in studies when participants restrict to 1 day/week).

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

AD diagnosis is projected to increase from approximately 5 million to 13.8 million Americans by 2050. The Alzheimer's Association estimates that healthcare costs for AD by 2050 could be 1.2 trillion dollars per year for Americans aged 65 years or older. There is marked focus on treating AD during the MCI phase, which precedes AD.

In the brain, insulin normally facilitates microvascular blood flow, glucose uptake, and glucose oxidation for adenosine triphosphate (ATP) generation. Insulin resistance (IR) is defined as a reduced cellular responsiveness to insulin, characterized by higher insulin levels needed to maintain glucose regulation in the periphery and certain brain areas. IR is found in MCI and AD patient brains. AD-related neuropathology, such as amyloid beta-containing plaques, progressive atrophy, and glucose hypometabolism first occur in brain areas that also have a high density of insulin receptors. Such areas include medial temporal lobe (MTL) and prefrontal cortex (PFC). Furthermore, as illustrated in the literature and previous work of the investigators, peripheral IR is associated with AD-like changes in MTL and PFC, including: 1) brain atrophy; 2) less glucose uptake; 3) accumulation of amyloid-beta, a hallmark of AD; and 4) increased phosphorylation of tau fibrils, another hallmark of AD. Finally, higher IR is related to deficits in memory performance and executive function.

These cognitive deficits can be ameliorated with 40 IU of intranasal insulin, which increases insulin processing in the brain with minimal peripheral effects, where MCI and AD patients show stable visuospatial working memory, as well as declarative learning and memory. One limitation of intranasal insulin is that it does not change obesity, which causes IR, and may therefore be only temporarily effective. As such, the investigators are interested in dietary regimens that can lower IR and may have long-term beneficial effects on AD neuropathology and cognitive output. Critically, intermittent calorie restriction (CR) diets reliably decrease body weight and IR in human adults. Intermittent CR protects neurons against dysfunction and degeneration in AD models. The underlying cellular and molecular mechanisms involve improved cellular bioenergetics and up-regulation of protein chaperones and antioxidant pathways in neurons. For example, 5-2 CR, a diet consisting of 5 days ad libitum followed by 2 consecutive days consuming 500-600 kcal, decreases IR beyond what is achieved with daily CR, and has a compliance rate of 83% versus 55% even by 6 months. It is also important to mention that no serious Adverse Events have occurred during past 5-2 CR studies.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

96

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Stati Uniti
    • Iowa
      • Ames, Iowa, Stati Uniti, 50011
        • Nutrition and Wellness Research Center
      • Iowa City, Iowa, Stati Uniti, 52242
        • University Of Iowa Hospitals And Clinics

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 70 anni a 85 anni (Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Years of age 70-85;
  2. Body Mass Index => 28 and < 40 and weight < 350 pounds;
  3. Mini-Mental State Examination >= 24;
  4. A subjective memory concern from the participant, caregiver/informant, or a clinician;
  5. An education-adjusted score for the Logical Memory II, paragraph A Wechsler Scale (16 years: 8-10; 8-15 years: 5-7; < 0-7 years: 2-3);
  6. A Clinical Dementia Rating - sum of boxes = 0.5;
  7. No deficits in activities of daily living;
  8. Consensus confirmation of MCI by senior investigators;
  9. An informant/caregiver that is informed about the study and will be present at study visits.

Exclusion Criteria:

  1. A history of a major cardiovascular event(e.g., heart attack);
  2. A history of cerebrovascular or other neurological disorders (e.g., stroke, epilepsy, multiple sclerosis, etc.);
  3. A history of substance abuse in the past 6 months;
  4. A history of eating disorders;
  5. A history of clinically significant endocrine disorders (e.g., hypothyroidism);
  6. A history of mood and anxiety disorders (e.g., Major Depressive Disorder, Generalized Anxiety Disorder, Bipolar disorder, etc.);
  7. Taking insulin;
  8. Current use of systemic corticosteroids;
  9. Current use of Warfarin;
  10. Having smoked tobacco products in the last 3 months;
  11. Contraindications for MRI (pacemakers, ferrous metal implants or shrapnel about the face or eyes, etc.);
  12. Other medical history that, in the opinion of the investigators, would constitute risk for subject participation;
  13. Hypertension, defined by a diastolic/systolic blood pressure of > 160/110;
  14. No current use of memantine or other Alzheimer's disease drugs.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Intermittent Calorie Restriction + Dietary Counseling

Participants will be asked to consume a single 530 kilocalorie shake (i.e., "High Calorie" Boost shake) on a given day for two consecutive days each week. Participants will eat ad libitum during the remaining 5 days. Participants will also receive Registered Dietitian of Nutrition (RDN) consultations about dietary modifications to induce moderate weight loss. Participants will utilize these recommendations in addition to shake consumption.

Subjects are also asked to follow RDN dietary recommendations.
Integratore alimentare: Meal-Replacement Therapy
The meal replacement shake, consumed once per day on two consecutive days, will over a given week lead to negative energy balance and induce weight loss.
Comportamentale: Dietary Counseling
A Registered Dietitian of Nutrition will provide consultation on how to induce moderate weight loss.
Comparatore attivo: Dietary Counseling
A Registered Dietitian of Nutrition (RDN) will consult with subjects about dietary modifications to induce moderate weight loss. Participants will utilize these recommendations.
Comportamentale: Dietary Counseling
A Registered Dietitian of Nutrition will provide consultation on how to induce moderate weight loss.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Body Weight
Lasso di tempo: 16 weeks
% change in BMI (kg/m2)
16 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Lasso di tempo: 16 weeks
Insulin resistance measured with fasting glucose and insulin
16 weeks
Functional Magnetic Resonance Imaging memory task activation
Lasso di tempo: 16 weeks
Regional brain activity induced by a memory task
16 weeks
Functional Magnetic Resonance Imaging executive function task activation
Lasso di tempo: 16 weeks
Regional brain activity induced by an executive function task
16 weeks
Cerebral blood flow
Lasso di tempo: 16 weeks
Regional cerebral blood flow assessed using Arterial Spin Labeling
16 weeks
Neural network functional connectivity
Lasso di tempo: 16 weeks
Degree of network strength in neural networks assessed at rest using Functional Magnetic Resonance Imaging
16 weeks
Mini-Mental State Examination
Lasso di tempo: 16 weeks
The construct for this total score is global cognitive performance, based on performance over a series of cognitive sub-domains. The unit is correct performance on a series of cognitive sub-domain tasks. The range is 0-30. A higher number is better.
16 weeks
NIH EXAMINER Dysexecutive Errors Composite Score
Lasso di tempo: 16 weeks
The construct for this composite score is overall impairment in various executive function domains. The unit is the total number of errors committed during several NIH EXAMINER tasks (Continuous Performance Task, Fluency, Flanker, Set Shifting). The range is 0-43. A higher score is worse.
16 weeks
California Verbal Learning Test
Lasso di tempo: 16 weeks
The construct for this factor is Verbal Memory. There are three sub-scales of main interest with the following units: 1) the total number of correctly recalled items in a 16-item list for a given trial where that list is read, spanning 5 trials ("CVLT Trials 1-5 Total"); 2) the total number of correctly recalled items in the same 16-item list after a 5 minute delay ("CVLT Short Delay"); and 3) the total number of correctly recall items in the same 16-item list after a 20 minute delay ("CVLT Long Delay"). The ranges are 0-80 for CVLT Trials 1-5 Total, 0-16 for CVLT Short Delay, and 0-16 for CVLT Long Delay. A higher number is better.
16 weeks
Digit Span - Forward and Backward
Lasso di tempo: 16 weeks
This construct probes working memory, a sub-domain of executive function. It requires participants to remember a list of numbers that gradually has more numbers added.
16 weeks

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Brain volume
Lasso di tempo: 16 weeks
Regional gray matter volume assessed with structural Magnetic Resonance Imaging
16 weeks
White matter tract integrity
Lasso di tempo: 16 weeks
Tract integrity assessed with Diffusion Tensor Imaging
16 weeks
NIH EXAMINER Verbal Fluency 1
Lasso di tempo: 16 weeks
The construct for this test is Phonemic Fluency. The unit is total number of words beginning with the letter 'F' produced in 60 seconds. The value range is variable but is typically 0-36. A higher score is better. There are two sub-scales: 1) Total Repetitions; and 2) Total Rule Violations. The value range is variable for either sub-scale. A higher value for either sub-scale is worse.
16 weeks
NIH EXAMINER Verbal Fluency 2
Lasso di tempo: 16 weeks
The construct for this test is Phonemic Fluency. The unit is total number of words produced beginning with the letter 'L' produced in 60 seconds. The value range is variable but is typically 0-30. A higher score is better.
16 weeks
NIH EXAMINER Categorical Fluency 1
Lasso di tempo: 16 weeks
The construct for this test is Categorical Fluency. The unit is total number of words produced related to animals in 60 seconds. The value range is variable but is typically 0-40. A higher score is better.
16 weeks
NIH EXAMINER Categorical Fluency 2
Lasso di tempo: 16 weeks
The construct for this test is Categorical Fluency. The unit is total number of words produced related to vegetables in 60 seconds. The value range is variable but is typically 0-30. A higher score is better.
16 weeks
NIH EXAMINER Insight
Lasso di tempo: 16 weeks
The construct for this test is Insight. The unit, in terms of % (0-100) is how well the participant thought they performed on the Fluency tasks relative to the population. We derive a sub-score that calculates the discrepancy between the stated % and the participant's actual % along the distribution. A larger discrepancy between %'s indicates worse performance.
16 weeks
NIH EXAMINER Spatial 1-Back Task
Lasso di tempo: 16 weeks
The construct for this test is Working Memory. The unit is the total number of correct responses over 30 trials, regarding if a square on the screen was in that position 1 trial ago. The range is 0-30. A higher score is better. A D-prime performance scale is also automatically computed, based on the difference between the z-transforms of the "hit rate" and the "false positive" rate. The range is typically -0.25 to 3.67. A higher score is better.
16 weeks
NIH EXAMINER Spatial 2-Back Task
Lasso di tempo: 16 weeks
The construct for this test is Working Memory. The unit is the total number of correct responses over 90 trials, regarding if a square on the screen was in that position 2 trials ago. The range is 0-90. A higher score is better. A D-prime performance scale is also automatically computed, based on the difference between the z-transforms of the "hit rate" and the "false positive" rate. The range is typically -1.12 to 2.48. A higher score is better.
16 weeks
NIH EXAMINER Saccades and Anti-Saccades
Lasso di tempo: 16 weeks
The construct for this test is Inhibition. The unit is the total number of correct eye movements toward or away from a visual stimulus on the screen. The range is 0-40. A higher score is better.
16 weeks
NIH EXAMINER Continuous Performance Task
Lasso di tempo: 16 weeks
The construct for this test is Inhibition. The units are the mean % accuracy and reaction time for choosing whether or not a symbol on the screen is the target symbol of interest (i.e., a "star"), which occurs during 100 trials. The accuracy range is 0-100%. The reaction time range is 400-2800 milliseconds. Higher accuracy is better and higher reaction time is worse. A sub-scale, False Alarm Errors, is also created. The unit is the number of times the participant makes the wrong selection during 100 trials. The range is from 0-100. A higher score is worse.
16 weeks
NIH EXAMINER Dot Counting
Lasso di tempo: 16 weeks
The construct for this test is Working Memory. The unit is the total number of correct number selections, where a participant selects the number of blue circles shown over 2-7 separate displays for a given trial, with a total of six trials conducted. The range is 0-27. A higher score is better.
16 weeks
NIH EXAMINER Set-Shifting
Lasso di tempo: 16 weeks
The construct for this test is Set-Shifting. The unit is the mean % accuracy and reaction time, over 104 trials, for selecting either the proper matching color or shape of a stimulus presented at the top of the screen when given a specific prompt (i.e., "shape" or "color"). The accuracy range is 0-100% and the reaction time range is 400-2800 milliseconds. A higher accuracy % is better and a higher reaction time is worse. A sub-scale is automatically computed that weights median reaction time and accuracy into a composite score. The range is 0-10. A higher number is better.
16 weeks
NIH EXAMINER Unstructured Task
Lasso di tempo: 16 weeks
The constructs for this test are Planning and Organizing. The unit is the total number of points that a participant accrues by completing a series of "high point" and "low point" puzzles within 6 minutes. The range is 0-1478. A higher score is better. Several sub-scales are automatically created, where a higher number is better: 1) the number of "high point" puzzles completed with a range of 0-21; 2) the number of low value puzzles completed with a range of 0-51; 3) The number of "high point" puzzles attempted with a range of 0-21; and 4) The number of "low point" puzzles attempted with a range of 0-51. Finally, a weighted composite score is created, where the unit is the value of the equation UTpct*log10(UTTotal+1), where UTpct is % of "high point" completed puzzles and UTTotal is the total number of points earned. The range is 0-2.7. A higher value is better.
16 weeks
NIH EXAMINER Flanker
Lasso di tempo: 16 weeks
The construct for this test is Inhibition. The unit is the mean % accuracy and reaction time over 24 trials, where the participant make a selection regarding where a middle arrow is facing amongst several other arrows facing the same way ("congruent") or the opposite way ("incongruent"). The accuracy range is 0-100% and the reaction time range is 500-3000 milliseconds. Higher accuracy is better and higher reaction time is worse. A composite sub-scale of performance is created basically based on log-rescaled median reaction time and accuracy. The range is 0-10. A higher number is better. Other sub-scales include accuracy and reaction time for congruent and incongruent trials. Ranges are variable. Higher accuracy is better and higher reaction time is worse.
16 weeks
NIH EXAMINER Social Norms Questionnaire
Lasso di tempo: 16 weeks
The construct for this test is Social Behavior/Cognition. The unit is the total number of correct responses to what would generally constitute proper or improper responses to various situations in mainstream heteronormative White culture in the United States. The range is 0-24. A higher score is better.
16 weeks
NIH EXAMINER Behavior Rating Scale
Lasso di tempo: 16 weeks
The construct for this scale is Social Behavior/Cognition. The unit is a total score over 9 behavioral domains (e.g., "agitation") shown by the participant during NIH EXAMINER testing, where each domain is scored on a 1-4 Likert scale of "absent" to "severe" based on operationalized criteria. The range is 0-36. A higher score is worse.
16 weeks
Trails A
Lasso di tempo: 16 weeks
The construct for this test is Attention. The unit is elapsed time taken to complete the test. The range is 10-300 seconds. A higher score is worse.
16 weeks
Trails B
Lasso di tempo: 16 weeks
The constructs for this test are Attention and Working Memory. The unit is elapsed time taken to complete the test. The range is 10-300 seconds. A higher score is worse.
16 weeks
Digit-Span Forward and Backward
Lasso di tempo: 16 weeks
The construct for this test is Working Memory. The unit is the total number of correct responses in remembering a 2-7 number sequence and relating the sequence either forward or backward. The range is 0-28. A higher score is better.
16 weeks
Digit Substitution
Lasso di tempo: 16 weeks
The construct for this test is Fluid Intelligence. The unit is the total number of correct symbol-to-number substitutions made over 93 symbol stimuli presented on a piece of paper. The range is 0-93. A higher score is better.
16 weeks
Benton Visual Retention Test
Lasso di tempo: 16 weeks
The construct for this test is Visual Memory. The unit is the total number of correctly drawn tableaus, each composed of arbitrary geometric shapes, that are presented to the participant for 10 seconds. The range is 0-10. A higher score is better.
16 weeks
Montreal Cognitive Assessment
Lasso di tempo: 16 weeks
The construct for this total score is global cognitive performance over several sub-domains, some of which vary from the Mini-Mental State Examination. The unit is correct performance on a series of sub-domain tasks. The range is 0-30. A higher number is better.
16 weeks
Clinical Dementia Rating
Lasso di tempo: 16 weeks
The construct for this Likert-scaled structured interview is global cognition and overall function, where the interview is conducted with the participant and a caretaker/informant. The unit is the sum of six Likert-scaled sub-domains of cognition and function ("CDR-sum of boxes"), where on the Likert-scale a 0 corresponds to cognitively unimpaired, 0.5 suggests Mild Cognitive Impairment, and 1-3 indicate mild to severe dementia. The range is 0-18. A higher score is worse. Six sub-domain scores (Memory, Orientation, Judgment and Problem Solving, Community Affairs, Home and Hobbies, Personal Care) are also tallied. The range is 0-3 for each sub-domain. A higher score is worse.
16 weeks
NIH EXAMINER Fluency Factor
Lasso di tempo: 16 weeks
The construct for this factor is Fluency, based on overall performance during 4 NIH EXAMINER Fluency tasks. The unit is a mean Z-Score calculated from 4 separate Z-scores based on the total correct for 4 Fluency NIH EXAMINER tasks. The range is -3 to 3. A higher score is better.
16 weeks
NIH EXAMINER Cognitive Control Factor Score
Lasso di tempo: 16 weeks
The construct for this composite score is Inhibition, based on overall performance during the NIH EXAMINER Flanker, Set-Shifting, and Saccade/Anti-Saccade tasks, as well as the total number of dysexecutive errors committed. The unit is a mean Z-score of Z-scored performance for those tests listed and a Z-score of total errors committed. The range is -3 to 3. A higher score is better.
16 weeks
NIH EXAMINER Working Memory Factor Score
Lasso di tempo: 16 weeks
The construct for this factor is Working Memory, based on overall performance during NIH EXAMINER tasks including Dot Counting and d-prime scales from the spatial 1- and 2-back tasks. The unit is a mean Z-score based on Z-scored values for total correct in Dot Counting and derived d-prime in each N-back task. The range is -3 to 3. A higher number is better.
16 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Iowa State University

Collaboratori

National Institute on Aging (NIA)

Investigatori

  • Investigatore principale: Auriel A Willette, Iowa State University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

8 maggio 2019

Completamento primario (Effettivo)

31 dicembre 2021

Completamento dello studio (Effettivo)

31 dicembre 2021

Date di iscrizione allo studio

Primo inviato

11 marzo 2019

Primo inviato che soddisfa i criteri di controllo qualità

11 marzo 2019

Primo Inserito (Effettivo)

13 marzo 2019

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

31 marzo 2022

Ultimo aggiornamento inviato che soddisfa i criteri QC

28 marzo 2022

Ultimo verificato

1 marzo 2022

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 201612732
  • R00AG047282 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi